Lung cancer is the most common cause of cancer death for men and women worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Systemic chemotherapy is a cornerstone of treatment in the management of stage IV NSCLC.
First-line chemotherapy typically consists of a platinum-based treatment. The optimum approach to long-term treatment beyond 4 to 6 cycles of chemotherapy is still evolving. Second-line chemotherapy given at the time of disease progression has shown clear survival advantages when compared with best supportive care alone. With the recent increase in the number of active and more tolerable agents available to treat NSCLC, there is renewed interest in the role of continuation of antineoplastic agents (continuation maintenance) or switching to a different agent (switch maintenance) after first-line chemotherapy.
This case-based review discusses the role of maintenance chemotherapy in the long-term management of advanced NSCLC.
Authors: Varughese S, Jahangir KS, Simpson CE, Boulmay BC, Lopez F
Read Full Article
